Novo introduces Ozempic in India
Digest more
The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a weight-loss treatment in 2021. “When I look at it right now, organically, their pipeline doesn’t convince me that this situation is manageable,
The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a patent dispute in India.
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)In the STEP UP programme, people with obesity taking Wegovy® 7.
2d
Alzheimer’s Trial Setback and Obesity Rivals Could Be A Game Changer For Novo Nordisk (CPSE:NOVO B)
In early December 2025, Novo Nordisk reported phase 3 Evoke and Evoke+ trial results showing oral semaglutide did not improve Alzheimer’s symptoms, while still achieving statistically significant but clinically modest reductions in disease-related biomarkers.
Data from Structure Therapeutics and WAVE Life Sciences show that threats to the incumbents’ dominance are on the way.
EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in the U.S., U.K., and other markets.
Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago. After years o
Feedback